Key Takeaways
- HSBC shifted its rating on Eli Lilly (LLY) from Hold to Reduce, lowering the price target from $1,070 down to $850
- Analyst Rajesh Kumar believes LLY shares are “priced to perfection” following a 20% rally in the past year
- HSBC reduced its obesity drug market size projection to $80–120bn by 2032, significantly below the consensus estimate of $150bn+
- Questions emerge around orforglipron launch projections, pricing dynamics, and dependence on direct cash-pay customers
- LLY shares declined 1.6% to $972.51 after the downgrade; competitor Novo Nordisk (NVO) has dropped 52% during the same timeframe
Eli Lilly has enjoyed an impressive rally. With shares climbing 20% over the last twelve months while competitor Novo Nordisk has surrendered more than half its market value, LLY appeared to be dominating the weight-loss pharmaceutical space. However, HSBC believes investors may be overly optimistic.
This Tuesday, HSBC’s Rajesh Kumar shifted his stance on Lilly to Reduce from Hold, simultaneously reducing his price objective to $850 from the previous $1,070. Shares retreated 1.6% to $972.51 following the announcement.
Kumar’s central thesis is straightforward: the stock has reached a valuation that leaves minimal margin for disappointment.
The downgrade centers on three primary risk factors. First is the actual size potential of the obesity treatment market. HSBC currently projects a total addressable market ranging from $80–120 billion by 2032. This figure sits substantially below the $150 billion-plus projection that many Wall Street analysts have incorporated into their models.
This discrepancy is significant. A reduced market opportunity ceiling translates to constrained revenue expansion potential relative to what’s already reflected in Lilly’s current stock price.
Orforglipron Launch Projections Appear Aggressive
The second risk factor involves Lilly’s forthcoming oral weight-loss medication, orforglipron. The treatment is anticipated to reach the market later this year and has sparked considerable investor enthusiasm — consensus projections for 2026 sales range from $1.1 billion to $1.3 billion.
HSBC questions these optimistic figures. Kumar stated that “the compliance and persistence of these drugs might disappoint,” observing that current estimates seem tied to a $1.5 billion inventory stockpile Lilly has already accumulated in preparation for the launch.
Inventory accumulation signals corporate confidence. However, it simultaneously elevates risk exposure should actual demand fall short of expectations.
Pricing Headwinds Are Emerging
The third area of concern involves pricing dynamics. Lilly confronts potential price reductions in 2026 stemming from intensifying competition, and HSBC highlighted “rising working capital intensity” alongside weakening “rebate dynamics” as red flags.
Kumar also examined the performance gap between Lilly’s and Novo Nordisk’s recent guidance — a divergence he notes has left most investors searching for explanations. His interpretation is that Lilly’s superior results have been fueled by the cash-pay distribution channel, where patients pay directly rather than through insurance coverage.
This channel demonstrates greater vulnerability to macroeconomic shifts and, according to HSBC’s analysis, could face disruption from AI-driven labor market transformations.
HSBC maintains a constructive outlook on the broader healthcare sector heading into the next quarter. However, Kumar considers Lilly’s risk-reward profile unattractive at present valuation levels.
LLY was changing hands at $972.51 when the downgrade was published, representing more than $120 above HSBC’s revised $850 price objective.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
